December 28, 2021, Simcere Pharmaceutical Group announced that SCR-6852 capsule, an orally selective estrogen receptor degrader (SERD) independently developed by Simcere，received the Clinical Trial Application (CTA) approval by the China National Medical Products Administration (NMPA) for the treatment of ER positive, HER-2 negative breast cancer.
Among all investigational SERD drugs worldwide, SCR-6852 unique molecule that can effectively cross blood-brain-barrier (BBB) is expected to provide new treatment choice for breast cancer patients with brain metastases.
About SCR-6852
SCR-6852 is a novel orally small-molecule SERD developed by Simcere with independent intellectual property rights. Compared with the first-generation SERD drug by intramuscular injection, this new oral drug avoids injection-induced pain and other related side effects while also showing good anti-tumor activities both in vitro and in vivo. In preclinical animal models, SCR-6852 showed a higher BBB penetration rate (4-10 times higher) than other similar investigational compounds, and improved survival of mice with intracranial breast cancer model. In vitro, It demonstrated robust inhibitory activities on ER-positive breast lines. SCR-6852, either as a single-agent or in combination with palbociclib, significantly inhibited the tumor growth of ER-positive breast cancer mouse models. Related data has been published at the 2021 American Association for Cancer Research (AACR) Annual Meeting.
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of known and unknown risks, uncertainties and assumptions. The forward-looking statements contained herein reflect the current judgment and views of Simcere Pharmaceutical Group Limited as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, or may not materialize, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements, whether as a result of new information, future events or otherwise, to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.